# US 2024/0199626 A1 · Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199626 A1
- Document ID: US20240199626A1
- Status: Published application
- Kind: A1
- Application number: 18/556,081
- Filed: 2022-04-19
- Published: 2024-06-20
- Earliest claimed: 2021-04-19
- Assignees: Oregon Health & Science University; The Board of Trustees of the Leland Stanford Junior University
- Applicants: Oregon Health & Science University; The Board of Trustees of the Leland Stanford Junior University
- Inventors: Sanjay Malhotra; Mallesh Pandrala; Dhanir Tailor; Arne A.N. Bruyneel; Mark Mercola; Anna P. Hnatiuk Hnatiuk
- Web page: https://patentgrep.com/patent/US20240199626A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 487/04: Ortho-condensed systems
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 233/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are compounds, pharmaceutical formulations, and methods for treatment of cancer, particularly including chronic myeloid leukemias, and neurodegenerative disorders in a subject.

## Claims

### Claim 1

A compound of Formula (I):
wherein R1 is selected from the group of H, C2-C6 alkyl, C3-C6 cycloalkyl, and —CH2-C3-C6 cycloalkyl; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is selected from the group of H, ethyl, n-propyl, isopropyl and cyclopropyl; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1, 2)

The compound of any of claims 1 and 2, wherein R1 is selected from the group of H, ethyl, isopropyl and cyclopropyl; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2)

The compound of any of claims 1, 2, and 3, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group of H, ethyl, and cyclopropyl.

### Claim 5 (depends on 1, 2, 3)

The compound of any of claims 1, 2, 3, and 4, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group of H and ethyl.

### Claim 6 (depends on 1, 2, 3, 4)

The compound of any of claims 1, 2, 3, 4, and 5, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group of H and isopropyl.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The compound of any of claims 1, 2, 3, 4, 5, and 6, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group of H and cyclopropyl.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The compound of any of claims 1, 2, 3, 4, 5, 6, and 7, or a pharmaceutically acceptable salt thereof, having the structure:

### Claim 9 (depends on 1, 2, 3, 4)

The compound of any of claims 1, 2, 3, 4, and 5, or a pharmaceutically acceptable salt thereof, having the structure:

### Claim 10 (depends on 1, 2, 3)

The compound of any of claims 1, 2, 3, and 6, or a pharmaceutically acceptable salt thereof, having the structure:

### Claim 11 (depends on 1, 2, 3)

The compound of any of claims 1, 2, 3, and 4, or a pharmaceutically acceptable salt thereof, having the structure:

### Claim 12

A compound of Formula (II):
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment of chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of any of claims 1-11 (claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11), or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 12)

A method of treatment of chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of inhibiting the activity of the BCR-ABL kinase protein in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 12)

A method of inhibiting the activity of the BCR-ABL kinase protein in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment of chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of one or more agents selected from the group of ponatinib, nilotinib, imatinib, dasatinib, bosutinib, rebastinib, and interferon alfa-2b; or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 12)

A method of treatment of chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of one or more agents selected from the group of ponatinib, nilotinib, imatinib, dasatinib, bosutinib, rebastinib, and interferon alfa-2b; or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment for chronic phase chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 12)

A method of treatment for chronic phase chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment of chronic phase chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of one or more tyrosine kinase inhibiting agents selected from the group of ponatinib, nilotinib, imatinib, dasatinib, bosutinib, and rebastinib; or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 12)

A method of treatment of chronic phase chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of one or more tyrosine kinase inhibiting agents selected from the group of ponatinib, nilotinib, imatinib, dasatinib, bosutinib, and rebastinib; or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment in a subject of chronic phase chronic myeloid leukemia with resistance or intolerance to at least one prior tyrosine kinase inhibitor, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of ponatinib; or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 12)

A method of treatment in a subject of chronic phase chronic myeloid leukemia with resistance or intolerance to at least one prior tyrosine kinase inhibitor, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of ponatinib; or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment in a subject of chronic phase chronic myeloid leukemia with resistance or intolerance to at least two prior tyrosine kinase inhibitors, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of ponatinib; or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 12)

A method of treatment in a subject of chronic phase chronic myeloid leukemia with resistance or intolerance to at least two prior tyrosine kinase inhibitors, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of ponatinib; or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment of accelerated phase chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of one or more tyrosine kinase inhibiting agents selected from the group of ponatinib, nilotinib, imatinib, dasatinib, bosutinib, and rebastinib; or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 12)

A method of treatment of accelerated phase chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of one or more tyrosine kinase inhibiting agents selected from the group of ponatinib, nilotinib, imatinib, dasatinib, bosutinib, and rebastinib; or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment of blast phase chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of one or more tyrosine kinase inhibiting agents selected from the group of ponatinib, nilotinib, imatinib, dasatinib, bosutinib, and rebastinib; or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 12)

A method of treatment of blast phase chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of one or more tyrosine kinase inhibiting agents selected from the group of ponatinib (ICLUSIG®), nilotinib (TASIGNA®), imatinib (GLEEVEC®), dasatinib (SPRYCELL®), bosutinib (BOSULIF®), and rebastinib; or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment of chronic myeloid leukemia with a T315l mutation in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of omacetaxine (SYNRIBO®); or a pharmaceutically acceptable salt thereof.

### Claim 32 (depends on 12)

A method of treatment of chronic myeloid leukemia with a T315l mutation in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of omacetaxine (SYNRIBO®); or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment of Philadelphia chromosome positive chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of nilotinib (TASIGNA®); or a pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 12)

A method of treatment of Philadelphia chromosome positive chronic myeloid leukemia in a subject, the method comprising administering to the subject in need thereof:
a) a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically effective amount of nilotinib (TASIGNA®); or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treatment in a subject of chronic myeloid leukemia that is resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof.

### Claim 36 (depends on 12)

A method of treatment in a subject of chronic myeloid leukemia that is resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating a neurodegenerative condition in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof.

### Claim 38 (depends on 12)

A method of treating a neurodegenerative condition in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a compound of any of claim 12, or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 36, 37)

The method of any of claims 36 and 37, wherein the neurodegenerative disease is selected from the group of Parkinson's Disease, Alzheimer's Disease, Down's syndrome, frontotemporal dementia, progressive supranuclear palsy, Pick's disease, Niemann-Pick disease, Parkinson's disease, Huntington's disease, dentatorubropallidoluysian atrophy, Kennedy's disease (also referred to as spinobulbar muscular atrophy), and spinocerebellar ataxia (e.g., type I, type 2, type 3 (also referred to as Machado-Joseph disease), type 6, type 7, and type 17)), fragile X (Rett's) syndrome, fragile XE mental retardation, Friedreich's ataxia, myotonic dystrophy, spinocerebellar ataxia type 8, and spinocerebellar ataxia type 12, Alexander disease, Alper's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Batten disease (also referred to as Spielmeyer-Vogt-Sjogren-Batten disease), Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, ischemia stroke, Krabbe disease, Lewy body dementia, multiple sclerosis, multiple system atrophy, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, Adult Refsums Disease (ARD), Sandhoff disease, Schilder's disease, spinal cord injury, spinal muscular atrophy, Steele-Richardson-Olszewski disease, and Tabes dorsalis.

### Claim 40 (depends on 37, 38)

The method of any of claims 37, 38, and 39, wherein the neurodegenerative condition is associated with, characterized by, or implicated by a mitochondrial dysfunction.

### Claim 41 (depends on 40)

The method of claim 40, wherein the neurodegenerative condition is selected from the group of Friedrich's ataxia, amyotrophic lateral sclerosis (ALS), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), myoclonic epilepsy with ragged red fibers (MERFF), epilepsy, Parkinson's disease, Alzheimer's disease, and Huntington's Disease.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically useful carrier or excipient.

### Claim 43 (depends on 12)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically useful carrier or excipient.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The use of a compound selected from any of claims 1-11, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41)

The use of a compound selected from any of claims 1-11, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in a method of treatment selected from those of any of claims 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 42.

### Claim 46 (depends on 12)

The use of a compound of claim 12, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament.

### Claim 47 (depends on 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 39, 41)

The use of a compound selected from claim 12, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in a method of treatment selected from those of any of claims 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 39, 41, and 42.

### Claim 48

A compound of Formula (III), wherein R1 is selected from the group of H and —OCH3:
or a pharmaceutically acceptable salt thereof.
